Feasibility of a multi-panel of epigenetic markers of fish growth
"Aquaculture, the process of controlled fish and shellfish cultivation, is a sustainable alternative to fisheries. The sector has seen tremendous growth and Nile tilapia is one of the most important commercially farmed species wor...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EPIMARK
Commercial feasibility of a kit for the identification of ep...
149K€
Cerrado
EPIFISH
INNOVATIVE EPIGENETIC MARKERS FOR FISH DOMESTICATION
2M€
Cerrado
AGL2016-78710-R
IDENTIFICACION DE MARCADORES EPIGENETICOS LIGADOS AL CRECIMI...
242K€
Cerrado
BES-2017-079744
IDENTIFICACION DE MARCADORES EPIGENETICOS LIGADOS AL CRECIMI...
93K€
Cerrado
EPIAQUA
Unravelling the epigenetic mechanisms underlying nutritional...
2M€
Cerrado
PID2021-128540OA-I00
SUSCEPTIBILIDAD DEL GENOMA DE LA DORADA A LA MANIPULACION EP...
153K€
Cerrado
Información proyecto EPISELECT
Duración del proyecto: 20 meses
Fecha Inicio: 2023-04-24
Fecha Fin: 2024-12-31
Líder del proyecto
NORD UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Aquaculture, the process of controlled fish and shellfish cultivation, is a sustainable alternative to fisheries. The sector has seen tremendous growth and Nile tilapia is one of the most important commercially farmed species worldwide. To date, the optimization of production yields is limited to traditional selective breeding programs, that exclusively focus on genetic markers. As a result, unknown variability in growth selection remains, which may be diminished through epigenetic selection.
Prof. Jorge Fernandes’ group has found evidence for the direct involvement of multiple categories of epigenetic markers in growth rate and size of Nile tilapia. During the ERC Consolidator project EPIFISH (#683210), Fernandes’ group observed important differences in expression levels of non-coding RNAs (ncRNAs): full-sibling groups of Nile tilapia with distinct growth rates expressed different sets of ncRNAs in muscle, despite being reared under the same environmental conditions.
EPISELECT will explore the technical and commercial feasibility of a multi-panel for the assessment of epigenetic markers for fish growth optimization. This multi-panel will assess the newly discovered ncRNAs in combination with the previously identified DNA modification markers. As a result, EPISELECT may improve selective breeding programs, leading to higher profitability and increased sustainability of the aquaculture sector.
To reach the proof-of-concept stage, we will:
1) Explore ncRNA markers for growth prediction and validate the multi-panel of epimarkers;
2) Define an IPR position and strategy;
3a) Assess the market size, added value, cost analysis, and commercialisation route of the novel multi-panel of epigenetic markers;
3b) Establish connections with aquaculture industry and embed the project for commercialisation."